CA 125 dan Pemakaian Klinis Dalam Penatalaksanaan Kanker Ovarium

Ninuk Dwi ariningtyas

Abstract

Today there are three types of ovarian cancer, namely epithelial cell tumors (70%), which are the largest part of the tumor, Germ cell tumors with a smaller frequency, and sex cord-stroma tumors which is the smallest proportion of about 8% of neoplasm. Ovarian cancer is characterized by unusual early symptoms, real symptoms at advanced stages and low survival rates. Therefore, ovarian cancer is the leading cause of death from gynecological cancer. Over the past decade, several studies have been directed at increasing outcomes of ovarian cancer by performing preclinical screening tests, determining the early stages of disease by using radiological examination or tumor marker serum. The purpose of screening for ovarian cancer is to reduce mortality by detection of stage 1 ovarian invasive epithelial cancer that is potential to be cured. Serum CA 125 measurements are often used to monitor disease status or predict residual disease. A number of cell surface antigens and serum proteins are produced by ovarian tumors and can be tested with monoclonal antibodies. Some of these tests have been clinically applied as a marker of disease and are useful in the detection of subclinical diseases and the diagnosis of recurrent ovarian cancer. Among the multiple biochemical markers in ovarian cancer, the most studied are CA 125. CA 125 is a surface glycoprotein detectable cells in more than 80% of cases of ovarian epithelial cancer. This test is clinically used in the evaluation of mass diagnostics in the ovaries, observation of response to treatment, and further evaluation of patients with ovarian cancer

References

Barlow TS, Przybyjski M, et al. (2006). The utility of presurgical CA 125 to predict optimal tumor Citoreduction of epithelial ovarian cancer. Int J Gynecol ; 16 :496-500

Beatrice WS, Kenneth OL. (2001). Molecular cloning of the CA 125 ovarian cancer antigen. J Biol Chem ; 276: 27371-27375

Duffy MJ, Bonfrer YM. (2005). CA 125 in ovarian cancer. Int J Gynecol Cancer ; 15: 679-691

Gaducci A, Cosio S, et al. (2008). Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol/ Hematol; 1191

Jacobs I, Bast RC Jr. (1989). The CA 125 tumour associated antigen : a review of the literature. Hum Reprod :4:1-12

Michelle RJ, Simon A . (2017). Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. www.journals.elsevier.com/gynecologic-oncology

Pectasides D, Papoxinis G. (2008). Adult granulose cell tumor of the ovary. Hellenic Cooperative Oncology Group HeCOG ; 28(2B): 1421-7

Rachel A, Donna L. (2017). Patient-centered research priorities in ovarian cancer : a systemic revive of potential determinants of guideline care. www.sciencedirect.com/science/article.

Rustin S, Bast RC, et al. (2004). Use of CA 125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clinical cancer Research;10 : 3919-3926

Shinichi T, Yasuo H, et al. (2005). CA 125 regression during neoadjuvan chemotherapy as an independent prognostic factor for survival in patiens with advanced ovarian serous adenocarsinoma. J Gynecol ; 96 : 143-149

Svetlana Mironov, Oguz Akin, Neeta-Pandit Askar. (2007). Ovarian Cancer, Radio Clin N Am 45 ; 149-166

Taylor KJW, Schwarts PE. (1993). Screening for early ovarian cancer, Departement of Diagnostic Radiology and Obstetry and Gynecology, Yale University

Tsuda H, Hashigachi, et Al. (2002). The CA 125 regression rate to predict overall survival differ between Paclitaxel contaiing regimen and non Paclitaxel regimen in patient with advanced ovarian cancer. Int J Gynecol Cancer ; 12:435-437

Woolas RP, Oram DH, et al. (1999). Ovarian cancer identified through screening with serum marker but not by pelvic imaging. Int J Gynecol Cancer ; 9: 497-501


DOI: http://dx.doi.org/10.30651/jqm.v2i2.1657